Illumina Core Illumina — Net Income increased by 4.0% to $209.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 27.4%, from $164.00M to $209.00M. Over 3 years (FY 2022 to FY 2025), Core Illumina — Net Income shows an upward trend with a 18.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase reflects strong operational performance and effective cost management, while a decrease suggests margin compression or operational challenges.
The residual profit of the core business segment after accounting for all operating expenses, taxes, and segment-specifi...
Segment-level operating profit or net income as reported by diversified life science firms.
ilmn_segment_core_illumina_net_income| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $120.25M | $120.25M | $120.25M | $120.25M | $138.00M | $138.00M | $138.00M | $138.00M | $116.00M | $442.00M | $741.00M | $175.00M | $164.00M | $214.00M | $227.00M | $201.00M | $209.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +14.8% | +0.0% | +0.0% | +0.0% | -15.9% | +281.0% | +67.6% | -76.4% | -6.3% | +30.5% | +6.1% | -11.5% | +4.0% |
| YoY Change | — | — | — | — | +14.8% | +14.8% | +14.8% | +14.8% | -15.9% | +220.3% | +437.0% | +26.8% | +41.4% | -51.6% | -69.4% | +14.9% | +27.4% |